SCHEMBL2118388

SCHEMBL2118388

Cc1ccc(-c2ccoc2)cc1N(C)S(=O)(=O)c1ccc(N)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.41
CYP2C9 P11712 3/20 0.41
KMT2A Q03164 1/20 0.40
C5AR1 P21730 1/20 0.38
GAA P10253 1/20 0.38
HSD17B1 P14061 1/20 0.36
HSD17B2 P37059 1/20 0.36
CYP2C8 P10632 1/20 0.36
CYP2C18 P33260 1/20 0.36
PIK3CD O00329 1/20 0.36
C1R P00736 1/20 0.35
PRSS1 P07477 1/20 0.35
PTGES2 Q9H7Z7 1/20 0.34
SCD O00767 1/20 0.34
MAPT P10636 1/20 0.33
MCOLN3 Q8TDD5 1/20 0.33
ALDH1A1 P00352 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2D6 P10635 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2119022 0.88 PSEN1 (0.46) LMNACYP2C9KMT2AC5AR1MAPT
SCHEMBL2117632 0.88 HSD17B1 (0.44) LMNACYP2C9KMT2AC5AR1GAA
SCHEMBL2117866 0.80 TAAR1 (0.47) LMNACYP2C9KMT2AC5AR1GAA
SCHEMBL2119431 0.78 LMNA (0.41) LMNACYP2C9KMT2AC5AR1GAA
SCHEMBL2122135 0.75 LMNA (0.41) LMNACYP2C9C5AR1GAAPIK3CD
SCHEMBL2118824 0.74 PTGES2 (0.47) CYP2C9KMT2APTGES2MAPTALDH1A1
SCHEMBL2118443 0.74 LMNA (0.38) LMNACYP2C9KMT2AC5AR1GAA
SCHEMBL25920653 0.71 C5AR1 (0.62) LMNACYP2C9C5AR1CYP2C8CYP2C18
SCHEMBL2119577 0.69 MAPT (0.54) LMNACYP2C9KMT2AC5AR1GAA
SCHEMBL2117311 0.68 HSD17B1 (0.43) LMNACYP2C9KMT2AC5AR1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120095024-A1 TOLUIDINE SULFONAMIDES AND THEIR USE ELARA PHARMACEUTICALS GMBH (DE) 2012-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120095024-A1 TOLUIDINE SULFONAMIDES AND THEIR USE HIF1AN, HIF1A, EGLN2 LMNA 2529/4885CYP2C9 3693/4885KMT2A 276/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.